| 翻訳と辞書 |
TiGenix
TiGenix is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its validated, proprietary platform of allogeneic, expanded, adipose-derived stem cells, or eASCs, in inflammatory and autoimmune diseases. TiGenix was founded in 2000 by Prof. Dr. Frank P. Luyten and Gil Beyen as a spin-off from the Katholieke Universiteit Leuven and the Universiteit Gent. In 2007, the Company was listed on the Euronext exchange in Brussels, Belgium. The Spanish stem cell company, Cellerix SA, was acquired in 2011. Corporate headquarters are in Leuven, Belgium, and it has operations in Madrid, Spain.〔FlandersBio | http://flandersbio.be/life-sciences-database/tigenix/〕
TiGenix aims to become a fully integrated biopharmaceutical company with research and development, manufacturing, and sales and marketing capabilities to commercialise its products in Europe. License and distribution partners are being sought to develop and commercialise its products in the United States and other regions.
==Cell Therapy and Tigenix==
After small molecules and large molecules (‘biologicals’), cell and gene therapy are the next wave of medicinal therapy development. Cell therapy is distinctive and promising for addressing unmet medical needs because it can be regenerative, that is it repairs and replaces tissue and organs which are damaged; and it can be immune-modulatory, that is it controls inflammation and can help the body to return to homeostasis (stable equilibrium). Tigenix is at the forefront of this new wave, with a marketed product and a pipeline of late stage assets. The pipeline is developed from the eASC platform, an allogeneic cell therapy model whose products are scalable and ready for use.
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「TiGenix」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|